アジア太平洋の骨粗鬆症治療薬市場

◆英語タイトル:Osteoporosis Drugs Market in the APAC Region 2015-2019
◆商品コード:IRTNTR4777
◆発行会社(リサーチ会社):Technavio
◆発行日:2014年12月3日
◆ページ数:73
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥291,200見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、アジア太平洋の骨粗鬆症治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、アジア太平洋の骨粗鬆症治療薬市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Osteoporosis
Osteoporosis is a disease that reduces of the mass and density of bone, and results in increased risk of fracture. In this disease, the risks related to fracture increases because of the increased permeability of the bones. Often, there are no symptoms observed until the first fracture occurs. Increase in age, low body weight, low sex hormones or menopause, and smoking are some of the risk factors associated with this disease.

TechNavio’s analysts forecast the Osteoporosis Drugs market in APAC to grow at a CAGR of 4.73 percent over the period 2014-2019.

[Covered in this Report]
The Osteoporosis Drugs market in APAC can be divided into two segments: Antiresorptives and Anabolics. This report covers the present scenario and the growth prospects of the Osteoporosis Drugs market in APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs that are available in the market.
TechNavio’s report, the Osteoporosis Drugs market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Osteoporosis Drugs market in APAC landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Amgen
• Eli Lilly
• Merck
• Novartis

[Other Prominent Vendors]
• F. Hoffmann La Roche
• GlaxoSmithKline
• Jiangsu Hengrui Medicine
• Pfizer Inc.
• Qingdao Chiatai Haier Pharmaceutical  

[Market Driver]
• Increasing Global Aging Population
• For a full, detailed list, view our report

[Market Challenge]
• Multiple Patent Expiries
• For a full, detailed list, view our report

[Market Trend]
• Increasing Awareness of Bone Health Education
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

07.Pipeline Snapshot

08.Epidemiology and Demography
08.1.1 China
08.1.2 Hong Kong
08.1.3 Japan
08.1.4 India

09.Market Segmentation by Drug Class

10.Market Assessment of Top Drugs
10.1 Prolia
10.1.1 Sales
10.2 Fosamax
10.2.1 Sales
10.3 Evista
10.3.1 Sales
10.4 Forteo
10.4.1 Sales
10.5 Zometa
10.5.1 Sales

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors

19.Key Vendor Analysis
19.1 Amgen
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Product Portfolio by Revenue 2013
19.1.5 Business Segmentation by Revenue 2012 and 2013
19.1.6 Geographical Segmentation by Revenue 2013
19.1.7 Business Strategy
19.1.8 Recent Developments
19.1.9 SWOT Analysis
19.2 Eli Lilly
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue
19.2.4 Sales by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Merck & Co. Inc.
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Business Strategy
19.3.7 Key Developments
19.3.8 SWOT Analysis
19.4 Novartis AG
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Revenue by Business Segmentation
19.4.5 Revenue Comparison 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis

20.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Osteoporosis Drugs Market in APAC 2013-2018 (US$ billion)
Exhibit 3: Clinical Trial Map of Conjugated Estrogens/Bazedoxifene
Exhibit 4: Clinical Trial Map of Viviant
Exhibit 5: Clinical Trial Map of Prolia
Exhibit 6: Clinical Trial Map of Romosozumab
Exhibit 7: Clinical Trial Map of LY2541546 (Blosozumab)
Exhibit 8: Population Increase in People Aged 50 Years Or Over By Country (million), 2013 to 2019
Exhibit 9: Osteoporosis Drugs Market in APAC Segmentation by Drug Class
Exhibit 10: Antiresorptives Drugs Segmentation
Exhibit 11: Bisphosphonates Drugs Segmentation
Exhibit 12: Amgen’s Prolia Global Revenue 2010-2013 (US$ million)
Exhibit 13: Merck’s Fosamax Global Revenue 2009-2012 (US$ million)
Exhibit 14: Eli Lilly’s Evista Global Revenue 2010-2013 (US$ million)
Exhibit 15: Eli Lilly’s Forteo Global Revenue 2010-2013 (US$ million)
Exhibit 16: Novartis Zometa Global Revenue 2010-2013 (US$ million)
Exhibit 17: Amgen: Business Segmentation by Revenue 2013
Exhibit 18: Amgen: Product Portfolio by Revenue 2013
Exhibit 19: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 20: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 21: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 22: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 23: Eli Lilly: Sales by Geography 2013
Exhibit 24: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 25: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 26: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 27: Novartis AG: Business Segmentation
Exhibit 28: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 29: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 30: Novartis AG: Revenue by Geographical Segmentation 2013



【掲載企業】

Amgen , Eli Lilly, Merck , Novartis, F. Hoffmann La Roche , GlaxoSmithKline , Jiangsu Hengrui Medicine , Pfizer Inc., Qingdao Chiatai Haier Pharmaceutical

【レポートのキーワード】

骨粗鬆症治療薬、アジア、骨吸収抑制、蛋白同化

【リサーチ方法】

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋の骨粗鬆症治療薬市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆